The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
This strategic move positions Sudeep Pharma to seamlessly integrate high-end premix capabilities with its mineral portfolio
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Akums invested Rs. 272 crore in capital expenditure during FY25
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Subscribe To Our Newsletter & Stay Updated
